CORC  > 过程工程研究所  > 中国科学院过程工程研究所
Micro- and Nanoencapsulated Hybrid Delivery System (MNEHDS): A Novel Approach for Colon-Targeted Oral Delivery of Berberine
Zhang, Lingzhi1,4; Li, Mingyan1,4; Zhang, Guiqiu1,4; Gao, Changxing1,4; Wang, Shengfang2,3; Zhang, Tingting1,4; Ma, Chen1,4; Wang, Lianyan3; Zhu, Qing1,4
刊名MOLECULAR PHARMACEUTICS
2021-04-05
卷号18期号:4页码:1573-1581
关键词berberine microencapsulation nanoencapsulation nanoparticle controlled release Eudragit dextran sulfate sodium-induced colitis drug delivery system
ISSN号1543-8384
DOI10.1021/acs.molpharmaceut.0c00970
英文摘要Berberine (BBR) is currently explored in the oral treatment of many disorders, especially in those involving inflammatory processes. Nanotechnology-based drug delivery systems are emerging as an effective approach for improving the poor oral absorption/bioavailability of BBR. To optimize the BBR immunoregulatory effects on a specific part of the gastrointestinal tract, here we describe a micro- and nanoencapsulated hybrid delivery system (MNEHDS) for colon-targeted oral delivery of BBR and test its therapeutic efficacy in a murine colitis model. The MNEHDS is formed by encapsulation of BBR-loaded poly(lactic-co-glycolic acid) nanoparticles into a pH-sensitive, BBR-pre-entrapped Eudragit FS30D matrix to form a hybrid microparticle composed of the BBR and BBR nanoparticles. Once in the colonic environment, the microencapsulated BBR is almost completely released for immediate action, while BBR nanoparticles can provide sustained release of BBR subsequent to their intestinal absorption. One dose of oral MNEHDS/BBR treatment results in significant attenuation of acute colitis induced by dextran sulfate sodium. The MNEHDS/BBR also proves to be effective during chronically induced colitis with two doses given 1 week apart. The improved efficacy is accompanied by decreased production of colon inflammation. Comparatively, oral treatment with one or two 7-day courses of free BBR has less effect on ameliorating either acute or chronic colitis. Thus, MNEHDS represents a novel delivery system for BBR, and potentially other therapeutic agents, to treat inflammatory bowel disease.
资助项目National Natural Science Foundation of China, China[31370922] ; National Natural Science Foundation of China, China[81973262] ; Beijing Natural Science Foundation, China[5131002] ; CAMS Major Collaborative Innovation Project, China[2016-12M-1-011] ; National Science and Technology Major Project of China[2016ZX10004001-005]
WOS研究方向Research & Experimental Medicine ; Pharmacology & Pharmacy
语种英语
出版者AMER CHEMICAL SOC
WOS记录号WOS:000637870700007
资助机构National Natural Science Foundation of China, China ; Beijing Natural Science Foundation, China ; CAMS Major Collaborative Innovation Project, China ; National Science and Technology Major Project of China
内容类型期刊论文
源URL[http://ir.ipe.ac.cn/handle/122111/48517]  
专题中国科学院过程工程研究所
通讯作者Wang, Lianyan; Zhu, Qing
作者单位1.Chinese Acad Med Sci & Peking Union Med Coll, Inst Mat Med, State Key Lab Bioact Subst & Funct Nat Med, Beijing 100050, Peoples R China
2.Northeast Forestry Univ, Coll Chem Chem Engn & Resource Utilizat, Harbin 150040, Peoples R China
3.Chinese Acad Sci, Inst Proc Engn, Key Lab Green Proc & Engn, State Key Lab Biochem Engn, Beijing 100190, Peoples R China
4.Chinese Acad Med Sci & Peking Union Med Coll, Inst Mat Med, Beijing Key Lab New Drug Mech & Pharmacol Evaluat, Beijing 100050, Peoples R China
推荐引用方式
GB/T 7714
Zhang, Lingzhi,Li, Mingyan,Zhang, Guiqiu,et al. Micro- and Nanoencapsulated Hybrid Delivery System (MNEHDS): A Novel Approach for Colon-Targeted Oral Delivery of Berberine[J]. MOLECULAR PHARMACEUTICS,2021,18(4):1573-1581.
APA Zhang, Lingzhi.,Li, Mingyan.,Zhang, Guiqiu.,Gao, Changxing.,Wang, Shengfang.,...&Zhu, Qing.(2021).Micro- and Nanoencapsulated Hybrid Delivery System (MNEHDS): A Novel Approach for Colon-Targeted Oral Delivery of Berberine.MOLECULAR PHARMACEUTICS,18(4),1573-1581.
MLA Zhang, Lingzhi,et al."Micro- and Nanoencapsulated Hybrid Delivery System (MNEHDS): A Novel Approach for Colon-Targeted Oral Delivery of Berberine".MOLECULAR PHARMACEUTICS 18.4(2021):1573-1581.
个性服务
查看访问统计
相关权益政策
暂无数据
收藏/分享
所有评论 (0)
暂无评论
 

除非特别说明,本系统中所有内容都受版权保护,并保留所有权利。


©版权所有 ©2017 CSpace - Powered by CSpace